Interleukin-7 (IL-7), the principal cytokine implicated in thymopoiesis and peripheral T-cell homeostasis, is presently under evaluation in human diseases characterized by persistent lymphopenia. Unexpectedly, prior to the eventual IL-7-driven T-cell expansion, all treated patients showe a profound T-cell depletion 24 hours following injection. The current study utilizes the Rhesus macaque model to investigate the mechanisms involved in this IL-7-induced T-cell depletion. We identify a new critical function of IL-7 that induces massive and rapid T-cell migration from the blood into various organs, including lymph nodes, parts of the intestine and the skin. This homing process was initiated following the induction of chemokine receptor expression by circulating T-cells and the production of corresponding chemokines in target organs. Finally, we demonstrate that the IL-7-induced cell cycling is initiated within these organs before T-cells migrate back into the blood stream, indicating that T-cell homing is required for in vivo IL-7 function.
INTRODUCTION
Interleukin 7 (IL-7), the cytokine that promotes precursor B-and T-cell maturation [1] [2] [3] and sustains peripheral T-cell homeostasis [4] [5] [6] , is currently in phase I-II trials in diseases characterized by persistent lymphopenia. Despite the fact that interim results from these investigations tentatively support the efficacy of this molecule in producing long term T-cell increases in patients, an unexpectedly strong T-cell depletion was observed in all treated patients during Day 1 of therapy ( 7 and Irini Sereti, personal communication). Similar transient T-cell depletion was previously observed in both CD4+ and CD8+ T-cell subsets in IL-2-treated HIV-1 infected patients. In this study, massive apoptosis was observed at the end of the IL-2 cycle coinciding with the peak of proliferation 8 . While apoptosis is not observed under physiological concentrations of IL-7 in culture, during the first hours following IL-7 injection in patients the pharmacological IL-7 plasma concentration may result in a different outcome. Otherwise, T-cell depletion may also be the consequence of a massive T-cell redistribution.
Various chemokine-chemokine receptor couples participate in specific T-cell homing into both lymphoid and non-lymphoid organs 9 . In particular, CCL19-CCR7, CCL21-CCR7 and CXCL12-CXCR4 are primarily implicated in recruiting T-cells into secondary lymphoid organs 10, 11 , while CCL20-CCR6 interaction drives T-cells to the gut 12 and CCL25 allows CCR9-expressing T-cells to home to the small bowel 12, 13 . Engagement of the chemokines with their receptors on the leukocyte membranes triggers intracellular signals resulting in tight adhesion of the migrating cells through integrins, extravasation from the blood stream into tissues along chemokine gradients, eventually allowing cell activation. Interestingly, in vitro IL-7 stimulation was shown to induce CXCR4 expression by naive T-cells, suggesting potential homing consequences 14 .
-4 -Contrary to the situation in the thymus, where IL-7 interaction with HSPG does not seem required 24 , HSPGs provide a docking site for IL-7 in the bone marrow, controlling its availability to B-cell precursors 23 . In the other sites of IL-7 production, the implications of local IL-7 concentration on its function remain to be clarified.
After confirming in the healthy Rhesus macaque model that the injection of recombinant glycosylated simian IL-7 (R-sIL-7gly) is, as in human patients, immediately followed by massive depletion of circulating T-cells, we investigated the consequences of R-sIL-7gly
injection on both T-cell apoptosis and T-cell homing.
MATERIALS AND METHODS

Animal care and treatment
The Rhesus macaques included in this study were handled in accordance with European guidelines for care and treatment of research animals and the experiments performed on them were approved by the ethics committee of the Institut Pasteur. The animals were seronegative for SIVmac, simian T-cell leukemia virus type 1, simian retrovirus type 1 (type D retrovirus), and herpes virus B. For all injections and blood draws, the animals were anesthetized with ketamine (Imalgène 1000, Mérial, Lyon, France).
In a first phase of the experiment, two healthy Rhesus macaques of Chinese origin (#14424 and #14694) and an animal (#17021) previously immunized against simian IL-7 received a single subcutaneous injection of recombinant glycosylated simian IL-7 (R-sIL-7gly; 80µg/Kg of body weight), a dose previously shown to stimulate T-cell expansion in both healthy and SIV-infected macaques 25, 26 . Macaque #17021, extensively immunized with 3 injections of non-glycosylated recombinant simian IL-7 and complete Freund adjuvant, demonstrated significant levels of anti-IL-7 neutralizing antibodies (>1/2500) at the time of the experiment.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Following R-sIL-7gly injection, blood samples (3ml on EDTA) were drawn from both treated animals at 6, 12, 48 and 96 hours, as well as at Day 7 and Day 14. In addition, two noninjected animals (#21045 and #26007) served as controls and were subjected to the same sampling protocol. Four months later, when all the measured parameters had returned to baseline levels, macaques #14424 and #14694 received a second injection of R-sIL-7gly.
Macaques #26007 and #21045 served as controls. Blood samples were drawn at 6, 12, 48 and 96 hours (H0 to H96), as well as at Day 7. Moreover, at H0, H6 and H24, axillary or inguinal lymph nodes were surgically removed from macaques #14424, 14694 and 26007 at H0, H6 and H24.
In a second phase of the experiment, 3 healthy Rhesus macaques were subcutaneously injected with R-sIL-7gly (80µg/Kg of body weight) and sacrificed at Day 1 (#26007-2 and #41127-2) and Day 7 (#40885-2). A fourth animal (#21045-2) without R-sIL-7gly injection was sacrificed as a negative control. For this experiment, we also used historical samples from The different monoclonal antibodies used in this study were: CD3-APC-Cy7, CD4-PercPCy5.5, CD28-PE, CD95-APC purchased from Becton-Dickinson (BD, Le-Pont-de-Claix, France); CD8-PE-Cy7, CD31biotin, strepatavidin-PE-Texas-RED and CD31-DY590 (proteogenix-Oberhausbergen, France); Ki67-fluorescein isiothiocyanate (FITC) and Bcl-2-FITC from Dako (Trappes, France); CCR7-FITC, CCR6-FITC, CCR9-FITC and CXCR4-FITC (R&D-Lille, france); caspase 8 and caspase 9 (ABCAM-Paris, France).
Immunohistochemy
Snap-freezing was performed using Cryomold (Tissue-Tek, Labonord-Templemars, France) and optimal cutting temperature compound (OCT Tissue-Tek). The cups were placed in isopentane and cooled in liquid nitrogen. Samples were then stored at -80°C until used.
Frozen tissue sections were utilized for immunohistochemical detection of CD3, CD127 and Ki67 molecules. Briefly, frozen tissue sections with a thickness of 4µm were prepared and mounted on glass slides. The sections were then air dried for 1 hour and fixed with acetone for 10 min. Prior to immunolabelling, the sections were fixed with acetone/methanol (50/50) for 5 min at room temperature (RT) and then re-hydrated with TBS pH 7.6 (Dako, Trappes, France) for 5 min at RT. Endogenous peroxydase activity was blocked with hydrogen peroxide 3% for 5 min at RT. To reduce non-specific background binding of the secondary antisera, sections were incubated for 20 min with rabbit serum. Sections were then incubated for 1h with primary antibody and subsequently incubated with biotinylated rabbit anti-mouse immunoglobulin (Dako, Trappes, France) for 30 min, followed by streptavidin biotin peroxydase complex for an additional 30 min. Each incubation was followed by a PBS wash. To facilitate visualization of the reaction, DAB was added to the sections which were then counterstained with Mayer's hematoxilin and mounted under Shandon synthetic montant (Thermo Fischer Scientific, Cergy Pontoise , France). Slides were examined using an Eclipse E800 microscope and a DXM1200 digital camera (Nikon, Champigny sur Marne, France).
Images were acquired using ACT-1 software (Nikon).
Chemokine quantification
Primers specific for each chemokine (CCL19, CCL20, CCL21, CCL25) and the HPRT gene HPRT quantifications were performed in independent experiments using the same first-round serial dilution standard curve. The chemokine and HPRT were quantified in triplicate for all samples studied. Chemokine mRNA concentration was normalized to HPRT mRNA in each sample. Since baseline chemokine expression levels might be different between animals, the results are presented as a fold expression over a reference organ chosen to present low and stable expression for the given chemokine in the four animals (i.e. jejunum for CCL19, skin for CCL20 and lung for both CCL21 and CCL25) 27 .
Plasma cytokine quantification
Cytokines in the plasma were quantified using the human 27-Plex TM and 23-Plex 
Statistical analysis
Statistical analyses (Mann-Whitney and paired Student T-tests) were performed using the 
RESULTS
Injection of R-sIL-7gly leads to an immediate drop in all peripheral T-cell subsets
Five healthy Rhesus macaques (#14424, #14694, #26007-2 #41127-2 and #40885-2) were subcutaneously inoculated with 80µg/Kg of body weight of R-sIL-7gly as described in the materials and methods section of this paper. As observed in IL-7 treated patients, all R-sIL7gly-treated animals demonstrated a strong peripheral lymphopenia during the first day following injection (Fig.1A ) 25, 28 . Notably, despite the fact that T-cell increase was not observed at Day 7 in macaque #40885 (designated a poor responder), the initial decrease in lymphocyte counts was also observed in this animal. In contrast, non-injected control animals (#21045 and #26007) sampled on the same schedule as the treated monkeys did not show a significant change in their circulating lymphocyte counts ( injection. In all treated monkeys, B-cell counts were much less affected by the R-sIL-7gly treatment ( Fig. 1D ).
We next analyzed the evolution of naive, central memory and effector memory T-cells as defined by CD95 and CD28 expression in CD4+ and CD8+ T cells 29 . In Rhesus macaques, all T-cell subsets express the IL-7 receptor α chain (CD127), likely explaining their sensitivity to IL-7. The CD4+ and CD8+ T-cell drop that occurs during the first day after RsIL-7 injection is a consequence of naive (CD95-CD28+), TCM (CD95+CD28+) and TEM (CD95+CD28-) T-cell depletion (Fig. 1E ).
Two non-exclusive hypotheses could explain such a drastic and sudden drop in circulating Tcell counts: (1) either lymphopenia was a consequence of massive cell death induced by pharmacological plasma cytokine concentration; and/or, (2) the injection of R-sIL-7gly
induced T-cell migration out of the blood.
R-sIL-7gly injection does not induce T-cell apoptosis
We first explored T-cell apoptosis in the blood (sampled at H0, H6 and Day 4 after R-sIL7gly injection) of macaques #14424 and #14694. The active form of either caspase 3, caspase 8 or caspase 9 (supplemental data 2) remained barely detectable in the tested samples, demonstrating that programmed cell death cannot account for the observed massive depletion of circulating T-cells. Moreover, the distribution of CD4+ and CD8+ T-cells in the axillary lymph nodes remained unchanged throughout the first days following R-sIL-7gly injection while CD127 expression was strongly down modulated (supplemental data 2). Again, caspase 3, 8 and 9 activation as well as DNA fragmentation remained negative in these organs (supplemental data 2). This again shows that despite good tissue distribution in the lymph nodes, R-sIL-7gly did not induce massive T-cell apoptosis in the secondary lymphoid organs. The absence of apoptosis in both lymph nodes and peripheral blood suggests that R-sIL-7gly-induced peripheral lymphopenia might be a consequence of T-cell redistribution from blood to organs. Since many lymphoid and non-lymphoid organs represent the usual homing sites for T lymphocytes, we further investigated the expression of molecules potentially involved in T-cell migration.
In vivo R-sIL-7gly-stimulated circulating T-cells over-express chemokine receptors
We investigated the expression of chemokine receptors implicated in T-cell homing into secondary lymphoid organs (CCR7 and CXCR4), the colon (CCR6) and the small bowel (CCR9), the principal homing organs targeted by T lymphocytes. As observed following in vitro IL-7 stimulation 14 , a strong increase of CXCR4 expression was observed in the CD4+
and, to a lesser extent, the CD8+ subsets ( Fig. 2A, top panel) .
In contrast, we did not observe significant modification of the expression level of CCR7 in the Finally, by 48 hours following R-sIL-7gly treatment a 1.5-to 2-fold increase of CCR6-expressing cell frequency was observed in both CD4+ and CD8+ subsets. In contrast, CCR9
expressing cell frequency was only increased in CD4+ T-cells (23-35% at Day 2 as compared to 8-10% at baseline) while remaining unchanged in CD8+ T-cells. Both CCR6 and CCR9 over expression were maintained for at least 4 days ( Fig. 2A, bottom panels) .
CCR6, CCR7, CCR9 and CXCR4 expression remained stable over time in both the noninjected monkeys and the immunized animal that received R-sIL-7gly injection (data not shown). These data demonstrate that R-sIL-7gly injection immediately triggers chemokine receptor expression by circulating T-cells, allowing T-cell redistribution.
The analysis of chemokine receptor expression in the various T-cell subsets showed that these cells respond differently to R-sIL-7gly stimulation by expressing a particular set of chemokine receptors (Fig. 2B) . CD4+ TCM demonstrated a major increase of CCR6, CCR9
and/or CXCR4 expression while CCR7 expression remained high in this subset (Fig. 2B) .
Similarly CXCR4, CCR6 and CCR9 were over-expressed by naive and TEM CD4+ T-cells (Fig. 2B) . In the CD8+ subsets, R-sIL-7gly treatment induces the over-expression of both CXCR4 and CCR6 in TCM and only CXCR4 in naive T-cells. In these 2 subsets, CCR7 expression was reduced upon treatment (Fig. 2B) . Finally, the expression of the four receptors in the TEM CD8+ subset remained low (Fig. 2B) .
Chemokines implicated in T-cell homing are locally produced in organs
To precisely analyze the different organs that may receive the migrating T-cells, macaques #26007-2 and #41127-2 were sacrificed 24 hours after IL-7 treatment (i.e. at the peak of Tcell depletion) and animal #40885-2 at Day 7 post-injection. At autopsy, axillary, inguinal and mesenteric lymph nodes, ileum, jejunum, colon, rectum as well as skin and lungs were sampled. Similar samples were taken from an animal sacrificed without R-sIL-7gly injection (#21045-2). Messenger RNAs coding for CCL19 (CCR7 ligand), CCL20 (CCR6 ligand), CCL21 (CCR7 ligand) and CCL25 (CCR9 ligand) were quantified in several small pieces (±1mm 3 ) from all tissue samples (Fig. 3) .
CCL21 mRNA levels were increased in the lymph nodes of macaques sacrificed at Day 1 and at Day 7 (13-and 14-fold over baseline values respectively, p=0.0004 and p=0.003, Fig. 3 ).
CCL19 expression was also elevated in the lymph nodes at Day 7 (12-fold increase over baseline, p=0.08). Of note, similar chemokine expression was observed in inguinal, axillary and mesenteric lymph nodes. Moreover, CCL19 was preferentially over-expressed in the (14-and 19- fold over baseline at Day 1 and 7, p=0.03, Fig. 3 ) and in the lungs (9-and 157-fold increase, p=0.02; Fig. 3 bottom panels) , while CCL21 was found over-expressed in the skin (59-and 28-fold over baseline at Day 1 and Day 7 respectively, p=0.02; Fig. 3 bottom panels) and in the jejunum (58-and 28-fold, p=0.06 and p=0.034; Fig. 3 bottom   panels) . In contrast, these chemokines remained at baseline levels in the other tested organs.
Similarly, CCL25 mRNA concentration was increased in the ileum and jejunum (9-and 29- fold at Day 1 and Day 7 in the ileum, p=0.034 and p=0.014; 7-and 54-fold in the jejunum, p=0.06 and p=0.02; Fig. 3 ).
Finally, CCL20 mRNA concentration rose in the colon and rectum (83-and 151-fold at Day 1 and Day 7 in the colon, p=0.016 and p=0.014; 3-and 5-fold in the rectum, p=0.027 at Day 7; Fig. 3 ).
These data demonstrate that the classic T-cell homing sites were responding to R-sIL-7gly injection by the induction of organ-specific chemokine mRNA production, again suggesting T-cell homing into these different organs.
R-sIL-7gly injection leads to the expression of various molecules implicated in T-cell trafficking
Using the human Bioplex™ assay, we next evaluated, the evolution of plasma concentration and CCL4 (1.5-to 2-fold) -molecules known to participate in T-cell homing into lymphoid organs 30,31 -was observed in both treated macaques (Fig. 4A) . Similarly, some molecules implicated in T-cell homing into non-lymphoid organs were also over-expressed following
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IL-7 treatment: CXCL9 (1.5-to 2-fold) and CXCL8 (5-to 10-fold) 32, 33 (Fig. 4B) . Finally, plasma concentrations of IL-1beta and IL-1RA, molecules implicated in transendothelial migration 34 , were augmented after R-sIL-7gly injection (10-to 20-fold and 10-to 100-fold, respectively; Fig. 4C ).
These data demonstrate that in addition to chemokine and chemokine receptor expression, RsIL-7gly injection leads to significant and reproducible in vivo production of various molecules involved in T-cell trafficking.
Circulating T-cells home to various peripheral organs
In order to confirm that R-sIL-7gly injection effectively triggers T-cell homing to the lymph nodes, gut and skin, tissue samples from animals #26007-2, #41127-2 (sacrificed 24 hours after R-sIL-7gly injection), #40885-2 (sacrificed at Day 7) and #21045-2 (non-injected animal) were subjected to immunohistological labeling with anti-CD3 monoclonal antibodies (Fig. 5 ). T-cell infiltration was observed in the skin and the lamina propria of the ileum, the colon and the rectum (Fig. 5A to 5F ). Quantifying CD3+ T-cells in 7 to 10 fields (0.09 mm These data confirmed that R-sIL-7gly induces T-cell homing into various non-lymphoid organs including the lamina propria of several parts of the gut (ileum, colon and rectum) and skin. Moreover, the expression of CCR7 and CXCR4 on circulating T-cells (Fig. 2) , the increase of CXCL12 plasma concentration (Fig. 4 ) and the production of CCL19 and/or CCL21 mRNA in lymph nodes (Fig. 3 ) also suggest homing into secondary lymphoid organs.
Similarly, the production of CCL19 in the ileum and the rectum and that of CCL21 in the jejunum (Fig. 3) suggest that R-sIL-7gly injection also triggers T-cell migration into the lymphoid follicles of the gut.
T-cells start cycling in the organs before migrating back into peripheral blood
Following the initial decrease in circulating T-cell numbers, we observed a rebound in T-cell counts starting at Day 4. In all T-cell subsets, the gain represents 50% to 150% of the initial circulating T-cell counts at Day 7 ( Fig. 1 and supplemental data 1 
DISCUSSION
In the last few years, therapeutic stimulation of the immune system has begun to have an increasingly important impact on medical practice. In particular, IL-2 and IL-7 are currently 7, 8 . The significant increase of circulating T-cells observed in most IL-2-treated HIV-1 infected patients is the net result of the increase of both proliferation and apoptosis 8 .
Consequently, such a treatment, even at its best, does not restore, and in fact probably reduces, T-cell repertoire diversity. Similarly, in the first patients treated with IL-7, the observed initial T-cell depletion could influence the efficacy of this treatment in restoring Tcell repertoire diversity ( 7 ). However, we have herein demonstrated that the initial T-cell depletion observed during R-sIL-7gly treatment is not due to massive T-cell apoptosis but is instead a consequence of massive cell redistribution.
The rapid T-cell redistribution observed in IL-7 treated macaques suggests that IL-7 concentration in the target organs is important for T-cell function. Indeed, higher IL-7
concentration is necessary to trigger in vitro T-cell cycling than to stimulate cell survival 14 . In vivo, higher local concentration might be achieved in organs where the cytokine is trapped on heparan sulfates at the stromal cell surface. Indeed, in preliminary experiments the injection of radiolabelled IL-7 in cynomolgus macaques led to a higher concentration in lymph nodes and spleen (20.8 to 32.8 ng/g of tissue), in the intestine (16.5, 19.1 and 21.2 ng/g in the bowel, colon and rectum, respectively) and in the lungs (18.7 ng/g) than in the blood (3.9 ng/g).
Differential expression of chemokine receptors by these different T-cell subsets (Fig. 2) as well as the chemokine production in non-lymphoid tissues such as the skin, lungs and intestine (Fig. 3) , suggests a particular function for T-cell homing in these tissues. Indeed, IL-7 participates in T-cell responses to antigenic stimulation [35] [36] [37] . Moreover, most of the molecules that were induced following IL-7 treatment were described as participating in Tcell homing into these organs during inflammatory reactions [38] [39] [40] [41] [42] . The expression patterns of chemokines/chemokine receptors suggest that naive and memory CD4+ T-cells are directed to the gut through CCR6/CCL20 and/or CCR9/CCL25 expression while all T-cell subsets (but showed that IL-7-induced CXCR4 over-expression coincides with an increased CXCL12 plasma concentration ( Fig. 2 and 4 ). In addition, we showed that R-sIL-7gly injection stimulates CCL19 and CCL21 production by secondary lymphoid organs in which all T-cell subsets could thus be recruited through constitutive CCR7 expression ( Fig. 2 and 3 ). Despite the fact that homing into lymph nodes is difficult to demonstrate in the macaque model, these data confirm observations made in mice, demonstrating the importance of lymph nodes in the regulation of naive T-cell homeostasis through IL-7 and CCL19 production 6 , but also through CXCR4/CXCL12 expression. Finally, the fact that at Day 1 post R-sIL-7gly injection, T-cell cycling occurs in the lymph nodes and intestinal follicles while it remains undetectable in blood further reinforces this conclusion and suggests that homing to these organs is crucial for complete in vivo IL-7 stimulation (Fig. 6C) .
The local chemokine production in the different target organs suggests that resident cells are responsive to IL-7. Interestingly, monocytes and dendritic cells were shown to be essential for IL-7 induced proliferation 43, 44 and, together with fibroblasts, to produce most of the proteins observed in R-sIL-7gly-treated macaques [44] [45] [46] [47] . Further investigation of the impact of IL-7 on the production of these molecules by cells located in tissues will help in understanding both homeostatic and inflammatory homing processes induced by IL-7.
For
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In summary, we have identified a novel property of IL-7 that when injected to healthy Rhesus macaques, rapidly initiates massive T-cell homing into secondary lymphoid organs and various epithelia. This effect is a direct consequence of both an increased expression of chemokine receptors (CXCR4, CCR6 and CCR9) by circulating T-cells and the initiation of chemokine transcription in the target organs. Homing processes were facilitated by the IL-7-dependant production of various molecules implicated in transendothelial cell migrations (IL-1β, IL-1RA, CCL3, and CCL4). However, other chemokine/chemokine receptors as well as other molecules implicated in T-cell trafficking can also be involved in the IL-7-induced cell migrations, in particular in the CD8+ subsets. By targeting circulating T-cells at the natural sites of IL-7 production, subsequently leading to T-cell proliferation, IL-7-induced T-cell homing appears to play an important role in the homeostatic regulation of peripheral T-cell pools. As previously observed, T-cell proliferation eventually leads to a 1.5 to 2.5-fold increase in circulating T-cells a week after IL-7 treatment 25, 28 . Interestingly, the IL-7-induced homing process drove circulating T-cells to different organs, including several parts of the gut where massive T-cell proliferation subsequently occurs.
Considering the results presented here and their possible impact on the treatment of HIV-1 infected patients, it would appear to be of great importance to evaluate the potential of IL-7, in combination with HAART in stimulating the T-cell repopulation of the gut, known to be massively T-cell depleted early in the course of HIV infection 48 and thereby opening the patient to the effects of opportunistic infections and malignancies which are frequently associated with a weakened immune system in this patient population. 
